January 17, 2023 01:32 PM EST
Deals
Pharma

PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

Katherine Lewin

News Reporter

PwC’s phar­ma in­dus­try trends analy­sis is here — and the au­dit com­pa­ny is pre­dict­ing sev­er­al neg­a­tives amid mod­est ex­pec­ta­tions for M&A, cov­er­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times